key: cord-0714995-v541uh89
authors: Tan, Chuen Wen; Fan, Bingwen Eugene; Teo, Winnie Z. Y.; Tung, Moon Ley; Shafi, Humaira; Christopher, Dheepa; Zheng, Shuwei; Peh, Wee Ming; Chan, Stephrene Seok Wei; Chong, Vanessa Cui Lian; Gallardo, Christian Aledia; Chang, Cheng Chieh Ray; Ling, Li Min; Tan, Jing Yuan; Lee, Ken Cheah Hooi; Phua, Ghee Chee; Cherng, Benjamin Pei Zhi; Low, Jenny Guek Hong; Ho, Vui Kian; Prasad, Vishnu; Wong, Lester Jung Long; Lim, Cheryl Xiu Qi; Chee, Yen Lin; Ong, Kiat Hoe; Lee, Lai Heng; Ng, Heng Joo; Yap, Eng Soo
title: Low incidence of venous thrombosis but high incidence of arterial thrombotic complications among critically ill COVID-19 patients in Singapore
date: 2021-03-08
journal: Thromb J
DOI: 10.1186/s12959-021-00268-9
sha: 050946aba6d56503b9b799861de25d5f54cfcad8
doc_id: 714995
cord_uid: v541uh89

BACKGROUND: Arterial and venous thrombosis are reported to be common in critically ill COVID-19 patients. METHOD AND RESULTS: This is a national multicenter retrospective observational study involving all consecutive adult COVID-19 patients who required intensive care units (ICU) admission between 23 January 2020 and 30 April 2020 in Singapore. One hundred eleven patients were included and the venous and arterial thrombotic rates in ICU were 1.8% (n = 2) and 9.9% (n = 11), respectively. Major bleeding rate was 14.8% (n = 16). CONCLUSIONS: Critically ill COVID-19 patients in Singapore have lower venous thromboembolism but higher arterial thrombosis rates and bleeding manifestations than other reported cohorts.

COVID-19 is associated with hypercoagulability [1] and a high incidence of thrombotic complications in critically ill patients [2] . Initial reports in Western populations suggest thrombotic rates as high as 49% despite thromboprophylaxis [3] while deep vein thrombosis (DVT) rate of 46% have been reported by the Chinese [4] . These disconcerting findings have prompted suggestion for empiric escalation of prophylactic anticoagulation therapy [3] but expert consensus [5, 6] and more recent data have questioned this rationale [7] . Of concern is hypercoagulability overlapping with sepsisinduced coagulopathy and thrombotic microangiopathy, resulting in a dynamic haemostatic environment with higher potential for bleeding complications from interaction with pharmacological thromboprophylaxis. Accurate profiling of thrombotic and bleeding complications in these patients is paramount for optimal case management and outcomes.

This study describes the thrombotic and bleeding manifestations among critically ill COVID-19 patients in Singapore.

This multi-center retrospective cohort study involved all eight public general hospitals with intensive care units (ICU) in Singapore-Alexandra Hospital (AH), Changi General Hospital, Khoo Teck Puat Hospital, National University Hospital, Ng Teng Fong General Hospital, Tan Tock Seng Hospital/National Centre for Infectious Disease campus, Sengkang General Hospital and Singapore General Hospital. From 23 January 2020 through 30 April 2020, all adult patients with COVID-19 confirmed by a respiratory SARS-CoV2 RT-PCR test and were admitted to any of the ICUs were identified. The study protocol was approved by the centralized institutional review board covering all participating hospitals (protocol no. CIRB 2020-2528) except AH which only contributed data on the total number of COVID-19 ICU admission and thrombotic events. Anonymized data was provided by each participating site and pooled for analyses. Laboratory results were based on the first results available when the patients were admitted to ICU. The primary outcome was any venous or arterial thrombotic event in the ICU. Other measures included (1) any thrombotic events throughout the period of hospitalisation, (2) major and minor bleeding events during hospitalisation, (3) factors associated with thrombotic and bleeding outcomes and (4) mortality. Venous thromboembolism (VTE) was diagnosed based on clinical suspicion and confirmation by Doppler ultrasound of the extremities or computed tomography. Myocardial infarctions (MI), type I ST elevation and non-ST elevation MI, were diagnosed based on dynamic changes in cardiac enzymes and electrocardiogram while ischaemic strokes were confirmed by MRI scans. Diagnosis of these arterial events were verified by attending specialists (cardiologists and neurologists respectively). Bleeding complications were graded using the modified World Health Organization (WHO) grading system [8] . Each hospital has its own standardised ICU bundles in which patients are started on pharmacological prophylaxis. However, the attending physicians are allowed clinical discretion and those patients deemed not suitable for pharmacological thromboprophyalxis are put on mechanical prophylaxis.

Descriptive statistics were used to analyse continuous and categorical variables. Logistic regression was used to evaluate potential risk factors for the secondary outcomes. All data analyses were performed using SPSS version 23.0 (IBM, USA).

One hundred eleven COVID-19 patients were admitted to the ICUs during the study period. The overall thrombotic rates in ICU were 11.7% (95% confidence interval (CI):7.0-19.0%) (n = 13) with 1.8% (95% CI: 0.5-6.3%) (n = 2) venous and 9.9% (95% CI: 5.6-16.9%) (n = 11) arterial events. Corresponding rates throughout hospitalisation, censored at 30 April 2020, were 18.0% (95% CI: 12.0-26.2%) (n = 20) with 6.3% (95% CI: 3.1-12.5%) (n = 7) venous and 11.7% (95% CI: 7.0-19.0%) (n = 13) arterial events. After the exclusion of cases from AH (n = 3, no thrombotic events), the remaining 108 patients contributed a total of 311.4 patient-weeks for further analysis ( Table 1 ). As of 30 April, 70 patients (64.8%) had been discharged while 9 had died (8%) and 30 (27.7%) were still hospitalized.

Two VTE events, comprising a lower limb DVT and a line-related upper limb DVT, were diagnosed in two patients in ICU, giving a VTE rate of 0.6 (95% CI: 0.1-2.3) per 100-person-weeks. For the entire duration of hospitalization, the cumulative VTE rate rose to 2.2 (95% CI: 0.9-4.6) per 100-patient-weeks. Of these, the majority were pulmonary embolism ( Table 2) . 75% of the patients received therapeutic anticoagulation after the diagnosis of VTE with 2 subsequently stopped due to bleeding complications.

The arterial thrombosis rate during ICU stay was 3.5 (95% CI: 1.8-6.3) per 100-patient-weeks. This increased marginally during the entire hospitalization to 4.2 (95% CI: 2.2-7.1) per 100-patient-weeks. These events were mainly MI of which one was fatal ( Table 2) .

The overall thrombotic complication rate in these 108 patients was 6.4 (95% CI: 3.9-9.9) per 100-patientweeks. 46.2% patients were receiving pharmacological thromboprophylaxis at the time of the events.

The major bleeding (WHO grade 3-4) rate was 5.1 (95% CI: 2.9-8.3) per 100-patient-week. (Table 2) with an overall bleeding rate was 6.4 (95% CI: 3.9-9.9) per 100-patient-days. One bleeding event, from an intracranial hemorrhage, was fatal.

Whilst no clinical factor was significantly associated with the occurrence of thrombotic events, the need of haemodialysis support in ICU and higher fibrinogen level were respectively associated with higher and lower risk for major bleeding events (Table 3a) . Mortality was associated with thrombosis but not bleeding (Table 3b ).

Although only two-thirds of our critically ill COVID-19 patients received thromboprophylaxis, the incidence rate of VTE was only 1.8%. This rate is far lower than similar published studies that included only objectively confirmed symptomatic VTE events [3, 9] . Several reasons could account for the lower VTE rates in our report. Arterial thrombosis (n = 13)

White blood count (× 10 9 /L) 8.5 (6.1-11.7) 8.3 (6.0-11.1) 11.3 (6.5-14.9) 10.5 (7.5-12.9)

Absolute lymphocyte count (×10 9 /L) 0.9 (0.6-1.5) 0.9 (0.6-1.5) 0.9 (0.6-1.5) 0.9 (0.6-1.7)

Absolute neutrophil count (×10 9 [10] . Our patients were also younger with fewer comorbidities and they tended to present to the hospital earlier in their course of illness [3, 4, 9] , which might have led to earlier interventions as reflected in the low median APACHE and SOFA scores on transfer to ICU. Of interest, the occurrence of further VTE events after ICU stay suggest the persistence of hypercoagulability [11] . Thromboprophylaxis measures hence should be continued for these patients throughout hospitalisation. However, a more intensified anticoagulation strategy for our patients was negated by the 14.8% major bleeding rate observed, which was considerably higher than other cohorts [7, 12] despite having lesser proportion of our patients on pharmacological thromboprophylaxis. The baseline characteristics of our patients were not notably different from other cohorts (references as above) apart Included ischemic heart disease, congestion heart failure and stroke from the ethnic factor in which our patients were predominantly Asian. The potential ethnic difference in bleeding events has also been observed in other settings including reports of higher bleeding rates among Asian patients taking warfarin for atrial fibrillation, compared with non-Asians counterparts [13] .

In contrast to VTE, our arterial event rates are high with mainly MIs occurring almost exclusively in the ICU, when the patients were the sickest. Unlike VTE, comparative arterial thrombotic rates in other COVID-19 cohorts are lower at 4% [3, 7] with mainly strokes rather than MIs. Myocardial injury in up to 30% of COVID-19 patients have been reported by some Chinese investigators but this was based on elevation of cardiac troponin levels [14] without verification of MI. Apart from ethnic differences, the baseline cardiovascular risk factors of our patients did not differ notably from existing literature [7] and thus the precise reason behind the higher rates seen in our population is not apparent currently.

This study is limited by its retrospective nature as with most other studies conducted under the present pandemic environment. There was no established imaging protocol for suspected VTE consistent across the hospitals. Similarly, clinical and laboratory data was not uniformly collected and trivial bleeds might have been missed. The small number of thrombotic and bleeding events also limited our statistical analysis of inference.

Our data is adequately robust to highlight the differences in thrombosis presentations and higher bleeding manifestations compared to other published cohorts. Our findings thus argue against the need for intensification of pharmacological thromboprophylaxis in similar Asian-predominant populations. Use of global coagulation assays [15] in critically ill COVID-19 patients to guide thromboprophylaxis warrant future consideration and exploration. Extended thromboprophylaxis during hospitalisation should also be considered. The role of antiplatelets and low dose direct anti-Xa inhibitors as cardio-protectants should be among future investigations.

Coagulopathy of coronavirus disease 2019

Thrombosis risk associated with COVID-19 infection. A scoping review

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis

Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevalence, risk factors and outcome

Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST guideline and expert panel report

Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19

COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection

Reporting results of cancer treatment

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Wu CC: incidence of venous thromboembolism in Asian populations: a systematic review

Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia

Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study

Stroke prevention in atrial fibrillation: an Asian perspective

Association of Coronavirus Disease 2019 (COVID-19) with myocardial injury and mortality

Thromboelastographic results and hypercoagulability syndrome in patients with coronavirus disease 2019 who are critically ill

The authors are grateful for the full support from all the participating hospitals and are greatly appreciative of the dedication of all the healthcare workers involved in the care of COVID-19 patients.

The authors do not declare any competing interests.Author details 1 Department of Haematology, Singapore General Hospital, Singapore, Singapore. 2 Department of Haematology, Tan Tock Seng Hospital, Singapore, Singapore. 3 Department of Laboratory Medicine, Khoo Teck Puat Hospital, Singapore, Singapore. 4 Department of Haematology-oncology, National University Cancer Institute, Singapore, Singapore. 5 Fast Program, Alexandra Hospital, Singapore, Singapore. 6 Department of Infectious Diseases, Changi General Hospital, Singapore, Singapore. 7 Department of General Medicine, Sengkang General Hospital, Singapore, Singapore. 8 Department of Intensive Care Medicine, Sengkang General Hospital, Singapore, Singapore. 9 Department of Infectious Diseases, National Centre for Infectious Disease, Singapore, Singapore. 10 Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore. 11 Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore. 12 Programme in Emerging Infectious Diseases, Duke-NUS, Singapore, Singapore. 13 Division of Medicine, Khoo Teck Puat Hospital, Singapore, Singapore. 14 Department of Medicine, Ng Teng Fong General Hospital, Singapore, Singapore. 15 Department of Laboratory Medicine, National University Hospital, Singapore, Singapore.

Protocol no. CIRB 2020-2528 under the Centralised Institutional Review Board of Singhealth.

All authors have no conflict of interest to declare.Authors' contributions CWT, BEF and ESY initiated and designed the study and had full access to all the study data and take full responsibility for the integrity of the data and accuracy of the data analysis. HJN initiated and critically revised the manuscript. WT collected and analysed the data and contributed to the writing of the manuscript. CYL and LHL critically revised the manuscript. MLT, HS, D, SZ, WMP, SSWC, VCLC, CAG, CCRC, LML, JYT, KCHL, GCP, JGHL, VKH contributed to data acquisition and interpretation. All authors reviewed and approved the final version of the manuscript.

This multicentre study was performed without any funding received.

For original data, please contact eng_soo_yap@nuh.edu.sg.

Ethics approval and consent to participate Ethics approval for this multicentre study was obtained from the SingHealth Centralised Institution Review Board.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.